Retrospective Analysis of Kampo Medicine's Role in Mitigating Endocrine Therapy Side Effects in Breast Cancer Patients: A Pilot Investigation - Summary - MDSpire
Advertisement
Retrospective Analysis of Kampo Medicine's Role in Mitigating Endocrine Therapy Side Effects in Breast Cancer Patients: A Pilot Investigation
To evaluate the efficacy of Kampo medicines in managing endocrine therapy-related side effects in breast cancer patients from July 2017 to June 2024.
Key Findings:
90% of complaints were related to vasomotor, motor/sensory, and psychiatric symptoms.
75% of patients reported NRS scores of 3 or less after 6 months.
KBG/KBGY was significantly associated with symptom relief (Hazard Ratio 4.18; p = 0.046).
Patients on KBG/KBGY experienced faster symptom improvement compared to those on other Kampo medicines (p = 0.022).
Interpretation:
Kampo medicines, particularly KBG/KBGY, are effective in alleviating side effects of endocrine therapy in breast cancer patients, significantly improving quality of life compared to other treatments.
Limitations:
Retrospective design may introduce bias.
Limited sample size restricts generalizability.
Potential confounding factors not fully controlled, and exclusion criteria may impact results.
Conclusion:
Kampo medicines, especially KBG/KBGY, show promise in reducing overall symptoms in breast cancer patients undergoing endocrine therapy, highlighting the need for further research.
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
